National Bank of Canada’s Fulcrum Therapeutics FULC Stock Holding History

National Bank of Canada’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.68K	Buy	459 +37	+9%	+$225	﹤0.01%	2726
2026 Q1	$3.23K	Sell	422 -21	-5%	-$195	﹤0.01%	2538
2025 Q4	$5K	Buy	443 +15	+4%	+$153	﹤0.01%	2436
2025 Q3	$3.94K	Sell	428 -45	-10%	-$326	﹤0.01%	2492
2025 Q2	$3.25K	Sell	473 -1,487	-76%	-$7.95K	﹤0.01%	2563
2025 Q1	$5.64K	Buy	1,960 +1,500	+326%	+$5.51K	﹤0.01%	2362
2024 Q4	$2.16K	Hold	460	–	–	﹤0.01%	2575
2024 Q3	$1.64K	Sell	460 -4,000	-90%	-$29.7K	﹤0.01%	2371
2024 Q2	$28.1K	Buy	4,460 +4,000	+870%	+$30.3K	﹤0.01%	1866
2024 Q1	$3.42K	Hold	460	–	–	﹤0.01%	2381
2023 Q4	$3.31K	Hold	460	–	–	﹤0.01%	2395
2023 Q3	$1.86K	Hold	460	–	–	﹤0.01%	2517
2023 Q2	$1.52K	Hold	460	–	–	﹤0.01%	2505
2023 Q1	$1.31K	Hold	460	–	–	﹤0.01%	2494
2022 Q4	$3.34K	Hold	460	–	–	﹤0.01%	2404
2022 Q3	$4K	Hold	460	–	–	﹤0.01%	2381
2022 Q2	$2K	Hold	460	–	–	﹤0.01%	2588
2022 Q1	$11K	Hold	460	–	–	﹤0.01%	2352
2021 Q4	$8K	Buy	+460	New	+$9.11K	﹤0.01%	2421

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

National Bank of Canada's FULC Position: Q2 2026 in Review

National Bank of Canada increased its Fulcrum Therapeutics (FULC) stake by 8.8% in Q2 2026, buying an estimated $225 and bringing the position to 459 shares worth $1.68K. The position accounts for ﹤0.01% of the portfolio, ranked #2726.

National Bank of Canada first reported a position in FULC in Q4 2021 and has held it in 19 quarters since. The position peaked at $28.1K in Q2 2024. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

National Bank of Canada held 459 shares of Fulcrum Therapeutics worth $1.68K as of Q2 2026.
National Bank of Canada bought 37 Fulcrum Therapeutics shares in Q2 2026, an estimated $225.
Fulcrum Therapeutics made up ﹤0.01% of National Bank of Canada's portfolio in Q2 2026, its #2726 holding.
National Bank of Canada first reported a position in Fulcrum Therapeutics in Q4 2021 and has held it in 19 quarters since.
National Bank of Canada's Fulcrum Therapeutics position peaked at $28.1K in Q2 2024.
155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on National Bank of Canada's 13F filing for Q2 2026, filed 10 Aug 2026.